Skip to main content

Advertisement

Table 3 Glucose and cardiovascular parameters in patients taking vildagliptin (100 mg daily) or sitagliptin (50 mg daily)

From: Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)

  vildagliptin sitagliptin p-value
HbA1c (%) 7.54 ± 0.93 7.64 ± 0.93 0.211
GA (%) 19.8 ± 3.47 20.1 ± 3.31 0.087
1,5AG (μg/mL) 7.68 ± 5.60 7.49 ± 6.16 0.389
IRI (μU/mL) 7.26 ± 4.44 6.94 ± 4.37 0.735
CPR (ng/mL) 2.14 ± 0.92 1.95 ± 0.78 0.302
U-CPR (μ/day) 97.0 ± 41.6 85.2 ± 39.9 0.008*
BNP (pg/mL) 7.00 ± 9.24 8.03 ± 8.40 0.283
PAI-1 (ng/mL) 36.6 ± 14.9 40.6 ± 23.1 0.231
  1. GA = glycoalbumin; 1,5-AG = 1,5-anhydroglucitol; IRI = immunoreactive insulin; CPR = C-peptide immunoreactivity; BNP = brain natriuretic peptide; PAI-1 = plasminogen activator inhibitor-1.
  2. Data are mean ± standard deviation. Paired-sample t-test. * p < 0.05.